raloxifene hydrochloride has been researched along with Dermatoses in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ju, JH; Kim, Y; Nam, Y; Rim, YA | 1 |
| Hoon, TS; Leok, GC; Yosipovitch, G | 1 |
1 review(s) available for raloxifene hydrochloride and Dermatoses
| Article | Year |
|---|---|
Suggested rationale for prevention and treatment of glucocorticoid-induced bone loss in dermatologic patients.
Topics: Adult; Age Factors; Aged; Calcitonin; Calcium; Controlled Clinical Trials as Topic; Densitometry; Diphosphonates; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Exercise; Female; Fractures, Bone; Glucocorticoids; Humans; Male; Meta-Analysis as Topic; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Skin Diseases; Time Factors; Vitamin D | 2001 |
1 other study(ies) available for raloxifene hydrochloride and Dermatoses
| Article | Year |
|---|---|
Anti-fibrotic effect of a selective estrogen receptor modulator in systemic sclerosis.
Topics: Animals; Cells, Cultured; Fibroblasts; Fibrosis; Humans; Leukocytes, Mononuclear; Mice; Raloxifene Hydrochloride; Scleroderma, Systemic; Selective Estrogen Receptor Modulators; Skin; Skin Diseases | 2022 |